万古霉素与急性肾损伤风险:系统综述与荟萃分析
该系统综述与荟萃分析检索1990年至2015年9月的PubMed与Cochrane Library,纳入比较静脉万古霉素与对照非糖肽类抗生素的随机对照试验和队列研究,对7项随机对照试验共4033例患者进行荟萃分析,中等质量证据提示万古霉素治疗与急性肾损伤风险升高相关,相对危险度为2.45(95%CI 1.69至3.55)。
要点
- 中等质量证据提示万古霉素与急性肾损伤风险升高相关,RR为2.45(95%CI 1.69至3.55)。
- 皮肤软组织感染与医院获得性肺炎及其他复杂感染患者的肾损伤风险相似。
- 肾功能并非任何试验的预设结局,报告偏倚风险不确定;多数研究对照为利奈唑胺,证据判定为间接。
核心结论
- 研究结果提示万古霉素与可测量的急性肾损伤风险相关,但证据强度为中等。
- 需要一项以肾功能为结局的随机对照试验才能得出明确结论。
研究设计与样本
- 系统综述与荟萃分析,纳入比较静脉万古霉素与对照非糖肽类抗生素且报告肾功能或肾损伤结局的随机对照试验和队列研究。
- 检索PubMed与Cochrane Library,检索时间范围为1990年至2015年9月。
- 由两名评价者提取数据并评估研究偏倚风险,由一名评价者裁定评估结果。
- 对7项随机对照试验共4033例患者进行荟萃分析。
主要发现
- 中等质量证据提示万古霉素治疗与急性肾损伤风险升高相关,相对危险度为2.45(95%CI 1.69至3.55)。
- 皮肤软组织感染患者的肾损伤风险与医院获得性肺炎及其他复杂感染患者相似。
- 报告偏倚风险不确定,因为肾功能并非任何试验的预设结局。
- 多数研究将万古霉素与利奈唑胺对照,证据判定以间接证据为主。
局限性
- 报告偏倚风险不确定,因为肾功能并非任何试验的预设结局。
- 多数研究将万古霉素与利奈唑胺对照,证据判定以间接证据为主。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Vancomycin has been in use for more than half a century, but whether it is truly nephrotoxic and to what extent are still highly controversial. The objective of this study was to determine the risk of AKI attributable to intravenous vancomycin. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a systematic review of randomized, controlled trials and cohort studies that compared patients treated with intravenous vancomycin with a control group of patients given a comparator nonglycopeptide antibiotic and in which kidney function or kidney injury outcomes were reported. PubMed and Cochrane Library were searched from 1990 to September of 2015. Two reviewers extracted data and assessed study risk of bias, and one reviewer adjudicated the assessments. A meta-analysis was conducted on seven randomized, controlled trials (total of 4033 patients). RESULTS: Moderate quality evidence suggested that vancomycin treatment is associated with a higher risk of AKI, with a relative risk of 2.45 (95% confidence interval, 1.69 to 3.55). The risk of kidney injury was similar in patients treated for skin and soft tissue infections compared with those treated for nosocomial pneumonia and other complicated infections. There was an uncertain risk of reporting bias, because kidney function was not a prespecified outcome in any of the trials. The preponderance of evidence was judged to be indirect, because the majority of studies compared vancomycin specifically with linezolid. CONCLUSIONS: Our findings suggest that there is a measurable risk of AKI associated with vancomycin, but the strength of the evidence is moderate. A randomized, controlled trial designed to study kidney function as an outcome would be needed to draw unequivocal conclusions.
引用
- Sinha Ray A, Haikal A, Hammoud KA, et al. Vancomycin and the Risk of AKI: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol. 2016. PMID: 27895134. doi:10.2215/CJN.05920616
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。